Preferred Label : Lm-tLLO-neoantigens Vaccine ADXS-NEO;
NCIt synonyms : Neoepitope-based Immunotherapeutic ADXS-NEO;
NCIt definition : A proprietary, personalized plasmid DNA-based cancer vaccine composed of a live-attenuated
strain of the Gram-positive bacterium Listeria monocytogenes (Lm) carrying a proprietary
plasmid vector encoding multiple, patient-specific, immunogenic neoepitopes fused
to a truncated form of the immunostimulant listeriolysin O (tLLO), with potential
immunostimulatory and antineoplastic activities. Upon administration of the Lm-tLLO-neoantigens
vaccine ADXS-NEO, the ADXS-NEO is taken up by antigen presenting cells (APCs), such
as dendritic cells (DCs), and the expressed tLLO-neoantigens fusion protein is processed
and presented to the immune system by both major histocompatibility complex (MHC)
I and II molecules. This activates the immune system to exert both innate and adaptive
immune responses involving the recruitment and activation of T-lymphocytes against
the tumor-associated antigens (TAAs) specifically expressed by the patient's tumor
cells, and inhibits the immunosuppressive tumor-infiltrating T-regulatory cells (Tregs)
and myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment (TME).
This results in tumor cell lysis. The various unique mutation-derived TAAs that are
used in ADXS-NEO are identified from a biopsy of the patient's tumor.;
Molecule name : ADXS NEO; ADXS-NEO;
NCI Metathesaurus CUI : CL551029;
Origin ID : C148380;
UMLS CUI : C4724988;
Semantic type(s)
- concept_is_in_subset
